More tools:Markets·Screener·Research·Chat

Cytosorbents Corp. (CTSO) Financial Statements

Cytosorbents Corp.
SIC 3841 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
FIGI BBG001SL7YQ0
XNAS · usd
6.85▲ 6.50 (1856.58%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close0.35
Day's Range6.75 – 7.44
52-Week Range0.30 – 7.44
Volume18.1K
Avg Volume307.3K
Share Statistics
Shares Outstanding
Employees129
ExchangeXNAS
Listed2005-05-17
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Cytosorbents Corp. (CTSO)
What is Cytosorbents Corp.'s Market Cap?
Cytosorbents Corp.'s Market Cap is $430.5M, based on as-reported figures from SEC (XBRL) filings.
What is Cytosorbents Corp.'s Enterprise Value?
Cytosorbents Corp.'s Enterprise Value is $443.3M, based on as-reported figures from SEC (XBRL) filings.
What is Cytosorbents Corp.'s Price / Sales?
Cytosorbents Corp.'s Price / Sales is 11.6×, based on as-reported figures from SEC (XBRL) filings.
What is Cytosorbents Corp.'s EV / Revenue?
Cytosorbents Corp.'s EV / Revenue is 12.0×, based on as-reported figures from SEC (XBRL) filings.
What is Cytosorbents Corp.'s EV / EBITDA?
Cytosorbents Corp.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Cytosorbents Corp.'s Revenue (TTM)?
Cytosorbents Corp.'s Revenue (TTM) is $37.1M, based on as-reported figures from SEC (XBRL) filings.
What is Cytosorbents Corp.'s Net Income (TTM)?
Cytosorbents Corp.'s Net Income (TTM) is -$18.2M, based on as-reported figures from SEC (XBRL) filings.
What is Cytosorbents Corp.'s EBITDA?
Cytosorbents Corp.'s EBITDA is -$11.8M, based on as-reported figures from SEC (XBRL) filings.
What is Cytosorbents Corp.'s Diluted EPS (TTM)?
Cytosorbents Corp.'s Diluted EPS (TTM) is -0.29, based on as-reported figures from SEC (XBRL) filings.
What is Cytosorbents Corp.'s EBITDA Margin?
Cytosorbents Corp.'s EBITDA Margin is -31.8%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenue, net——
YoY growth+0.2%+1.6%——
Cost of goods sold
Gross profit
% of revenue73.2%69.2%——
Operating expenses
Research and development, net of grant income
Selling, general and administrative
Restructuring———
Total operating expenses
% of revenue100.6%103.5%——
Loss from operations
% of revenue-27.4%-34.3%——
Other income (expense)
Interest expense, net
Gain (loss) on foreign currency transactions
Total other income (expense), net
Net income (loss)
% of revenue-45.9%-57.9%——
Basic net income (loss) per common share (in dollars per share)
Diluted net income (loss) per common share (in dollars per share)